

SWIXX APPOINTS PAVEL CHISTYAKOV MD GM RUSSIA AND REGIONAL DIRECTOR CIS & EURASIA REGION

SWIXX ANNOUNCEMENT NO. 39

September 14th, 2021

Baar, Switzerland – Swixx BioPharma SA announced today that Dr. Pavel Chistyakov will join Swixx BioPharma SA as GM Russia and Regional Director for Eurasia & CIS, effective September 20th, 2021. Among Pavel’s key responsibilities will be integrating and leading Swixx’s Russia operations – now numbering approximately two hundred people based in two locations. All of Swixx’s Russian business units and functional heads based in Russia will have solid line or dotted line reporting to Pavel. In addition to his Russia GM role, Pavel will spearhead the establishment of Swixx operations across the Eurasia & CIS region. Swixx is currently registering new legal entities in Belarus, Kazakhstan and Uzbekistan and the company intends to expand its coverage further across the region in the coming years.

Pavel Chistyakov comes to Swixx as a successful biopharma executive with an enviable reputation. He has deep experience in senior roles across the region. Most recently, Pavel has been VP for Greece, Russia and Turkey at Italfarmaco. Prior to that, Pavel spent four years at Sanofi as Trade and Revenue Director Russia, Central Asia and Caucasus. Pavel has also served as GM of Pierre Fabre Russia for eight years and as GM for Ipsen of Russia, Central Asia and Caucasus for the last three years of his nine years tenure in Ipsen. Pavel will be based in Moscow and will report to Swixx’s CEO, Jean-Michel Lespinasse.

“Let me warmly welcome Pavel to Swixx,” commented CEO Jean-Michel Lespinasse. “I’ve known Pavel for several years and have admired from afar his professional management style, many competencies and his evident success. I have long been eager to work more closely with him, and I am delighted that this opportunity has arisen and that he has joined Swixx. Pavel will bring to our Eastern Region proven leadership skills, seasoned judgement and a solid knowledge of oncology, rare disease and specialty, along with a background in consumer health / open market. Pavel has built excellent biopharma teams in the past and I am sure that with the myriad talented colleagues we already have at Swixx Russia as a base, he will help us build Swixx into the region’s pre-eminent partner of choice for MNC biopharma. I wish Pavel every success.”

About Swixx Biopharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, and Russia. With 600 employees and sales exceeding €270 million in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated commercialization platform for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit www.swixxbiopharma.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321